ATAI Stock Summary and Trading Ideas (Ataibeckley | NASDAQ:ATAI)

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Ataibeckley trades on the NASDAQ stock market under the symbol ATAI.

As of October 19, 2026, ATAI stock price was flat at $7.35 with million shares trading.

ATAI has a beta of 0.37, meaning it tends to be less sensitive to market movements. ATAI has a correlation of 0.00 to the broad based SPY ETF.

ATAI has a market cap of $2.73 billion. This is considered a Mid Cap stock.

Last quarter Ataibeckley reported $2 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.

In the last 3 years, ATAI traded as high as $7.45 and as low as $1.03.

ATAI has outperformed the market in the last year with a price return of +34.1% while the SPY ETF gained +17.3%. ATAI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2.8% and 0.0%, respectively, while the SPY returned +2.5% and -0.3%, respectively.

ATAI support price is $7.35 and resistance is $7.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATAI shares will trade within this expected range on the day.